idw – Informationsdienst Wissenschaft
Nachrichten, Termine, Experten
Nachrichten, Termine, Experten
The German Research Foundation is funding the ‘OncoEscape’ Collaborative Research Centre at the University of Freiburg for a further funding period. It is researching the fundamentals of new immunotherapies for cancer.
On 21 November 2025, the German Research Foundation (DFG) announced that it would fund the existing Collaborative Research Centre (CRC) 1479 ‘Oncogene-driven immune escape (OncoEscape)‘ at the University of Freiburg for a further funding period of three and a half years. The CRC investigates how tumour cells manage to escape the immune system and how this can be prevented. These findings could lead to new, sustainably effective cancer therapies. The participating research groups are based at the Medical Centre – University of Freiburg, the University of Freiburg, the M3 Research Centre at the Tübingen University Hospital, the German Cancer Research Center in Heidelberg and the Georg Speyer Haus in Frankfurt.
New approaches to treatment resistance
“Over the past four years, we have been able to show for several types of cancer that there is a link between cancer-inducing mutations and cancer cells evading the immune response. These discoveries have led to new therapeutic approaches that are currently undergoing clinical trials. The extension of the Collaborative Research Centre is a great recognition,” says CRC spokesperson Prof. Dr Robert Zeiser. He heads the Division of Tumour Immunology and Immune Regulation at the Department of Internal Medicine I at the Medical Centre – University of Freiburg and is a member of the Cluster of Excellence CIBSS – Centre for Integrative Biological Signalling Studies at the University of Freiburg. In 2025, he received the Gottfried Wilhelm Leibniz Prize.
“Inhibiting oncogenic signal transduction to enhance immunotherapy against cancer is a new approach that could help overcome resistance to treatment,” says CRC co-spokesperson Prof. Dr Tilman Brummer from the Institute of Molecular Medicine and Cell Research at the University of Freiburg. “Implementation in clinical trials is ensured by the excellent infrastructure in the Early Clinical Trial Unit (ECTU) of the Department of Internal Medicine I at the Medical Centre – University of Freiburg,” adds Prof. Dr Justus Duyster, Medical Director of the Department of Internal Medicine I at the Medical Centre – University of Freiburg.
Invisible to the immune system
In normal tissue, the frequency with which cells divide is precisely controlled by stimulating oncogenes and inhibiting tumour suppressor genes. However, if oncogenes become genetically overactivated or tumour suppressor genes are lost, a normal cell transforms into a cancer cell. Both processes alter intracellular signal transduction, which is described by the umbrella term “oncogenic signalling.” This leads to tumour growth and, later, to increased genetic instability. As a result, the tumour cell can develop mechanisms to become invisible to the immune system or to silence the immune cells. These mechanisms are summarised under the term “immune escape.”
“The renewed funding for the Collaborative Research Centre confirms the strength of medical research in Freiburg,” says Prof. Dr Lutz Hein, Dean of the Medical Faculty at the University of Freiburg. “The extension of the CRC will allow researchers to experimentally test new therapeutic approaches against cancers that are resistant to immunotherapy.”
https://www.dfg.de/de/service/presse/pressemitteilungen/2025/pressemitteilung-nr...
Contact:
Office of University and Science Communications
University of Freiburg
Tel.: 0761/203-4302
kommunikation@zv.uni-freiburg.de
https://uni-freiburg.de/en/collaborative-research-centre-on-novel-cancer-therapi...
Prof. Dr. Robert Zeiser heads the Division of Tumour Immunology and Immune Regulation at the Departm ...
Copyright: CIBSS
Merkmale dieser Pressemitteilung:
Journalisten
Medizin
überregional
Buntes aus der Wissenschaft
Englisch
Prof. Dr. Robert Zeiser heads the Division of Tumour Immunology and Immune Regulation at the Departm ...
Copyright: CIBSS
Sie können Suchbegriffe mit und, oder und / oder nicht verknüpfen, z. B. Philo nicht logie.
Verknüpfungen können Sie mit Klammern voneinander trennen, z. B. (Philo nicht logie) oder (Psycho und logie).
Zusammenhängende Worte werden als Wortgruppe gesucht, wenn Sie sie in Anführungsstriche setzen, z. B. „Bundesrepublik Deutschland“.
Die Erweiterte Suche können Sie auch nutzen, ohne Suchbegriffe einzugeben. Sie orientiert sich dann an den Kriterien, die Sie ausgewählt haben (z. B. nach dem Land oder dem Sachgebiet).
Haben Sie in einer Kategorie kein Kriterium ausgewählt, wird die gesamte Kategorie durchsucht (z.B. alle Sachgebiete oder alle Länder).
